This Popular Cheese Product Is Being Recalled For a Very Serious Reason—Here's What to Know
Food recalls are never a fun experience. As consumers, we're forced to check our labels carefully, and if we have the recalled item in our possession, we either return it for a refund or discard it completely.
But not every food safety issue starts as a full-fledged recall. This week, for example, the U.S. Food and Drug Administration (FDA) announced a recall of a select batch of Boar's Head deli products—though the agency has yet to classify the severity.
😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔
According to the official notice, 65 cases, roughly amounting to 780 packages (each carrying 12 8-ounce packages) of Boar's Head Smoked Gouda cheese were distributed despite having a mislabeling issue. The recalled cheese products were produced by the Alpine Slicing and Cheese Conversion Company out of Wisconsin, and distributed to stores in the state of Florida.
For those out of the loop with recalls, a mislabeling issue can mean a number of things. At worst, it involves the omission of a major allergen or ingredient from the label—posing serious health risks for people with food allergies or dietary restrictions. At best, it's a less serious error, like a mislabeled flavor or an inaccurate photo on the packaging, which doesn't pose a danger but still warrants a recall to uphold consumer transparency and company standards.
While the severity of the recall is still being determined, and no further information about the mislabeling has been provided, it's reassuring that the issue is limited to one state. The recalled cheese was sold in 8-ounce packages and found in most major store refrigerators. It does not affect Boar's Head Smoked Gouda sliced at the deli counter, and no other products have been included.If you think you have a package of Boar's Head Smoked Gouda Cheese at home, check for UPC 0 42421-50006 6, code 03 SEP 25 F, and 'Distributed by Brunckhorst Co., NY, NY 11206." While the recall has not yet been officially classified, the FDA advises consumers not to eat the product out of an abundance of caution—either throw it away or return it to the place of purchase for a full refund.
Otherwise, as the issue progresses and more information becomes available, we'll report back to keep things up to date. The last thing anyone wants is to kick off the summer with a foodborne illness—or worse, for someone with an allergy to have a serious reaction to something that could've been avoided.This Popular Cheese Product Is Being Recalled For a Very Serious Reason—Here's What to Know first appeared on Parade on Jul 14, 2025
This story was originally reported by Parade on Jul 14, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
3 hours ago
- Washington Post
West Virginia's near-total abortion pill ban upheld by federal court
A divided federal appeals court on Tuesday allowed West Virginia to restrict access to mifepristone, the pill used to end pregnancies that has emerged as a focal point of legal battles over abortion. The decision marks the first time a federal appeals court has allowed a state to strictly limit the drug, teeing up a key test of states' powers to ban medication approved by the Food and Drug Administration.
The Hill
4 hours ago
- The Hill
Appeals court upholds West Virginia's medication abortion ban
A divided federal appeals court panel on Tuesday upheld West Virginia's ban on medication abortion, ruling that the law does not conflict with the Food and Drug Administration's ability to regulate the drug. The U.S. Court of Appeals for the Fourth Circuit dismissed mifepristone manufacturer GenBioPro's effort to strike down West Virginia's near-total abortion ban in a 2-1 decision. The court ruled FDA's approval of mifepristone did not preempt West Virginia's law. GenBioPro produces a majority of the mifepristone sold in the United States, and has held FDA approval for generic mifepristone since 2019. GenBioPro argued that FDA's authority to impose regulations on the prescription and distribution of mifepristone superseded state efforts to restrict access to medications. A lower court ruled against the company, which then appealed the decision. Circuit Judge J. Harvie Wilkinson wrote that a 2007 federal law 'leaves the states free to adopt or diverge from West Virginia's path' and it 'falls well short of expressing a clear intention to displace the states' historic and sovereign right to protect the health and safety of their citizens.' The ruling is the first time a federal appeals court has said states can restrict use of mifepristone. Twenty-eight states restrict access to medication abortions, according to the reproductive health nonprofit Guttmacher Institute. The Supreme Court upheld access to mifepristone last year, when it unanimously dismissed a lawsuit seeking to roll back changes FDA made in 2016 and 2021 to expand access. 'We respect the fact that appellant and some amici have argued that access to mifepristone is important to the health of women in the course of their reproductive choices,' Wilkinson wrote. 'Our objection is not to the substance of this point, but to the venue in which it is advanced.' Wilkinson was appointed by President Reagan. He was joined by U.S. District Judge Rossie Alston, an appointee of President Trump. 'The court is allowing the state to continue putting those seeking medication abortion care in harm's way,' GenBioPro CEO Evan Masingill said in a statement. 'The panel's ruling allows states to restrict access to medications that FDA has deemed safe and effective, threatening a dangerous ripple effect on the availability of essential medications in this country. As we have always made clear, GenBioPro will not stop fighting to ensure all people can access safe, evidence-based healthcare.' West Virginia Gov. Patrick Morrisey (R) said in a statement he was 'proud to see a victory in this case.' 'West Virginia can continue to enforce our pro-life laws and lead the nation in our efforts to protect life. We will always be a pro-life state!' he said. In a dissent, Circuit Judge DeAndrea Gist Benjamin said the state's law 'erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress.' Benjamin, who was appointed by former President Biden, added that 'the twin sensitivities of abortion access and states' rights cannot influence our willingness to recognize the Food and Drug Administration's (FDA) clear authority in this area.' 'By criminalizing medical providers and prohibiting medication abortions, then, West Virginia has exceeded the ability to regulate abortion as established in Dobbs and has trespassed on the FDA's authority to regulate the safe use of and unburdened access to mifepristone,' Benjamin wrote.
Yahoo
4 hours ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
